No Video/Audio Available.

Avita treats more US patients with Recell
October 19, 2016 10:40 AM

The US Food and Drug Administration has made a decision which is beneficial to medical technology company, Avita Medical Ltd (ASX:AVH).

The FDA has increased the number of patients who can be treated for burns, cosmetic and reconstructive procedures – using Avita’s ReCell regenerative medical device. However, use of Recell is only allowed under special compassionate use protocols.

Avita says this protocol is triggered when the patient’s treating doctor believes there are no suitable alternative treatments.

This decision allows the company to treat up to 48 patients who don’t have enough healthy skin to undergo standard skin grafts. The company says, so far, there have been 34 compassionate cases in which patients were treated using ReCell.

Avita posted a net loss of $8.8 million at 30 June 2016.

Comment on this story
Full Name:
Type the characters you see in the picture below.
Letters are not case-sensitive

Latest Finance News


Company News